Skip to main content
. 2018 Feb 22;8:3494. doi: 10.1038/s41598-018-21348-3

Figure 1.

Figure 1

Inhibition by citalopram of platelet aggregation induced by Horm collagen (N = 7 blood donors) and U46619 (N = 6 blood donors). (a) Example aggregation traces, illustrating concentration-dependent inhibition of collagen- and U46619-induced platelet aggregation by (RS)-citalopram. Arrowheads indicate the addition of agonist. (b) Collagen and U46619 concentration-response curves showing inhibition by (RS)-citalopram of the maximum extent of aggregation. (c) (RS)-, (R)- and (S)-citalopram inhibited the maximum extent of aggregation induced by 1 µg mL−1 collagen or 0.2 µM U46619 with similar inhibitory potencies (pIC50). 3-way ANOVA was performed with IBM SPSS v.23 (Effect 1 (fixed) = citalopram preparation {(RS), (R), (S)}; Effect 2 (fixed) = agonist {collagen, U46619}; Effect 3 (random) = donor {N = 7 (collagen), N = 6 (U46619)}). The results indicated no difference in the pIC50 of the three citalopram preparations (P = 0.95, F = 0.054, degrees of freedom (df) = 2, 27. H0: μRS = μR = μS; H1: μRS ≠ μR ≠ μS). Statistical evidence for a difference in the pIC50 values between collagen and U46619 was weak (P = 0.080, F = 3.314, df = 1, 27. H0: μcollagen = μU46619; H1: μcollagen ≠ μU46619).